

Korea's Samsung Biologics launches development platforms for enhanced therapeutic efficacy

26 September 2024 | News

New technology platforms to proactively address evolving industry trends and enable high-quality development



South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has launched a series of proprietary development platforms as part of continued efforts to ensure high-quality development and provide client-tailored services.

S-AfuCHO, introduced at BioProcess International 2024, is a cell line platform that can generate afucosylated antibodies that exhibit enhanced antibody-dependent cellular cytotoxicity (ADCC) activity for increased therapeutic efficacy. The platform removes the core fucose from Fc N-glycans through knockout of the host (FUT8) gene to achieve higher ADCC activity while retaining desired titers, stability, and product quality.

S-OptiCharge is an upstream process platform that can modulate a molecule's charge variant distribution. Modifications can occur at any step of the manufacturing process, impacting product safety and efficacy. The platform minimises charged variants within samples while maximising the main molecular form to ensure safe therapeutic effects. By optimising media, additives, and process parameters and using a thorough screening procedure, S-OptiCharge ensures high product quality through tight control over critical quality attributes to achieve optimal charge variant distribution.